Sanofi(SNY)

PARIS, FrancePharmaceutical1 H-1B visas (FY2023)

View 1,145 open jobs Website LinkedIn Careers Page

Focus: Sanofi is a global Big Pharma company with 91,000 employees headquartered in Paris, France, operating across small molecules, biologics, immunology, oncology, vaccines, and rare diseases.

Immunology Oncology Neurology Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

91,000

Open Jobs

1145+245 this month

Hot — 1677 jobs added in 30d

Net +245 (1677 new, 1432 removed). Aggressive expansion phase.

Should You Work at Sanofi?

AI assessment

Sanofi is a stable, global Big Pharma employer with strong portfolio depth, but significant patent cliff exposure on core products demands careful evaluation of long-term role security.

Why Work Here

Strong presence in vaccines and immunology with established market leadership and global reach—meaningful therapeutic impact at scale
Diverse therapeutic portfolio (diabetes, oncology, rare diseases, vaccines) provides broad career path options across R&D, commercial, and manufacturing

Data completeness

5/9 — Partial

Company HealthWatch

Pipeline

Early-stage

50 total

LOE Risk

3 imminent

FEXINIDAZOLE

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

LANTUS SOLOSTAR

Type 1 & 2 Diabetes Mellitus

$3.2B

LOE Approaching

Sanofi's largest revenue driver, but facing biosimilar erosion and approaching loss of exclusivity; represents ~47% of company revenue.

Help build intelligence for Sanofi

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Actively hiring across 15 departments with 546 open roles; commercial and manufacturing departments showing significant growth momentum

Watch Out For

Extreme revenue concentration (47% from one insulin franchise) creates structural vulnerability to patent cliff and biosimilar competition post-2030
Limited H1B sponsorship in 2023 (only 1 approval, 0 denials) may constrain visa-dependent talent mobility compared to peers

Generated by Claude from Sanofi's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LANTUS

Type 1 & 2 Diabetes Mellitus

$736M

LOE Approaching

Secondary insulin franchise in decline due to LOE timeline and biosimilar competition.

TOUJEO SOLOSTAR

Type 1 & 2 Diabetes Mellitus

$542M

Peak

Higher-concentration insulin formulation at peak sales; provides some portfolio diversification within diabetes space.

DUPILUMAB

Atopic Dermatitis, Asthma, Chronic Rhinosinusitis

Peak

Blockbuster immunology/inflammation asset with multiple Phase 3 and Phase 4 programs; critical growth driver as insulin portfolio declines.

MULTAQ

Atrial Fibrillation, Atrial Flutter

$409M

Peak5.0yr

Established cardiovascular asset with patent exclusivity through 2031; solid mid-tier revenue contributor.

AUBAGIO

Multiple Sclerosis

$354M

Peak8.1yr

Mature MS therapeutic with extended LOE window; supports neurology franchise diversification.

Pipeline & Clinical Trials

Investigational Procedures

Sphingomyelin Lipidosis

N/A

Clinical Trials (1)

NCT04106544A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)

N/A

Efluelda® Pre-filled syringe

Influenza Immunization

N/A

Clinical Trials (1)

NCT07282795Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe

N/A

Kidney Information Network for Disease Research and Education

ESRD

N/A

Clinical Trials (1)

NCT03321604Kidney Information Network for Disease Research and Education

N/A

Observatory on Elderly Patients "Les S.AGES"

Diabetes Mellitus, Type 2

N/A

Clinical Trials (1)

NCT01065909Observatory on Elderly Patients "Les S.AGES"

N/A

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Optic Neuritis

N/A

a live attenuated chimeric JE vaccine

Japanese Encephalitis

N/A

Clinical Trials (2)

NCT02526550Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX

Phase 4

NCT02602652Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials

Peripheral Arterial Occlusive Disease

N/A

Clinical Trials (1)

NCT01135797Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials

N/A

Flublok Quadrivalent influenza vaccine RIV4

Influenza

N/A

Clinical Trials (1)

NCT04460781Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring

N/A

Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registr

Acute Leukemia

N/A

Clinical Trials (2)

NCT01362985Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor

N/A

NCT01362972Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor

Bevacizumab

Lung Cancer

N/A

Clinical Trials (5)

NCT00208546Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer

Phase 3

NCT00335595Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients

AZD6244

Thyroid Cancer

N/A

DUPIXENT®

Asthma

N/A

Clinical Trials (5)

NCT06099704Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis

N/A

NCT04287608Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

N/A

Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

Meningitis

N/A

Clinical Trials (4)

NCT01270503Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines

Phase 4

NCT00483574Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients

Prostatic Neoplasms

N/A

Clinical Trials (1)

NCT01076751Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients

N/A

RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment

Hypertension

N/A

Plerixafor

Bone Marrow / Autologous Transplants

N/A

Clinical Trials (5)

NCT05087212Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

Phase 4

NCT02006225Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.

Dupilumab - Standard Dose

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

N/A

Clinical Trials (1)

NCT06892704Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.

N/A

A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatmen

Asthma

N/A

Clinical Trials (1)

NCT05070663A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)

N/A

Nasopharyngeal sampling

Bordetella Pertussis, Whooping Cough

N/A

Clinical Trials (1)

NCT03388034Pertussis Immunization Programs in Low Income Countries - Ivory Coast

N/A

Sepraspray

Adhesion Prevention

N/A

Clinical Trials (3)

NCT00813397Manageability and Safety Assessment of Sepraspray in Abdominal Surgery.

N/A

NCT00624390Sepraspray™ Laparoscopic Myomectomy Study

N/A

Brigham and Women's Rheumatoid Arthritis Sequential Study

Rheumatoid Arthritis

N/A

Alglucosidase alfa GZ419829

Glycogen Storage Disease Type II

N/A

Clinical Trials (1)

NCT04848779A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

N/A

Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 m

Primary Hypercholesterolaemia and Mixed Dyslipidaemia

N/A

Clinical Trials (1)

NCT05129241Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector

N/A

Blood sampling

Septic Shock

N/A

Clinical Trials (3)

NCT06469359Analyzes of Nasal Tissue-resident Memory Immune Cells and Peripheral Memory Cells Able to Migrate to Airway Tissues (MUCOVAC)

N/A

NCT02638779REAnimation Low Immune Status Markers

N/A

intradermal pholcodine allergy test in cases

Neuromuscular Blocking Agents Anaphylaxis

N/A

Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients

Medication Non-adherence

N/A

Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical

Heparin-induced Thrombocytopenia

N/A

Non-interventional Translational Study in Mild, Moderate and Severe Acne Patients

Acne

N/A

Clinical Trials (1)

NCT07411638Non-interventional Translational Study in Mild, Moderate and Severe Acne Patients

N/A

Venous Thromboembolism Taskforce Audit Program

Venous Thrombosis

N/A

Clinical Trials (1)

NCT00535171Venous Thromboembolism Taskforce Audit Program

N/A

Observational study

Myopathy

N/A

Clinical Trials (5)

NCT04023708Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy

N/A

NCT06786130Societal Burden Associated With Type 1 Diabetes in Canada

Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease

Healthy

N/A

Clinical Trials (1)

NCT02447627Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease

N/A

6 Minute Walk Test

Aged

N/A

Delay between MS onset and introduction of first line DMT

C10.114.375.500

N/A

Clinical Trials (1)

NCT03308994Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration

N/A

Sepraspray

Abdominal Adhesions

N/A

Clinical Trials (1)

NCT00665730Evaluation of the Safety and Effectiveness of Sepraspray™ in Reducing Post-surgical Adhesions

N/A

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Hematologic Disorder

N/A

Blood sample

Dermatitis Atopic

N/A

Clinical Trials (4)

NCT03784898Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

Phase 4

NCT00298428Biological Efficacy of Clopidogrel After Implantation of Drug-eluting Stents (SPACE)

N/A

Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in German

Chlamydia Trachomatis

N/A

Clinical Trials (1)

NCT07002047Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany

N/A

Alfuzosin

Kidney Stones

N/A

Clinical Trials (1)

NCT00583258A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones

N/A

Meningococcal

Meningitis

N/A

Clinical Trials (5)

NCT02864927Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea

Phase 4

NCT02591290Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects

Phase 4

Zolpidem CR

Dementia

N/A

Clinical Trials (1)

NCT00814502Zolpidem CR and Hospitalized Patients With Dementia

N/A

Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine

Arsenic--Toxicology

N/A

Clinical Trials (1)

NCT03930017Pregnancy, Arsenic and Immune Response

N/A

Turkey Thrombotic Thrombocytopenic Purpura Disease Registry: National Multicenter Study

TTP - Thrombotic Thrombocytopenic Purpura

N/A

Clinical Trials (1)

NCT05950750Turkey Thrombotic Thrombocytopenic Purpura Disease Registry: National Multicenter Study

N/A

Financial incentives for increasing physical exercise

Sedentary Lifestyle

N/A

Clinical Trials (1)

NCT01043757Financial Incentives for Increasing Exercise

N/A

Stamaril®

Yellow Fever

N/A

Clinical Trials (1)

NCT03541694Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea

N/A

Heparin Induced Thrombocytopenia: Pharmacoeconomics

Heparin Induced Thrombocytopenia (HIT)

N/A

Clinical Trials (1)

NCT00456001Heparin Induced Thrombocytopenia: Pharmacoeconomics

N/A

Screening DIVA - Diffuse Vascular Disease

Peripheral Vascular Diseases

N/A

Pediatric and Ambulatory Research in Infectious Diseases

Otitis

N/A

Quadrivalent Intradermal Influenza Vaccine

Pregnancy

N/A

Clinical Trials (1)

NCT02554409Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry

N/A

Seprapack Sinus Dressing

Chronic Sinusitis

N/A

Clinical Trials (1)

NCT00140608Efficacy of Seprapack Sinus Dressing Versus No Dressing in the Prevention of Intranasal Adhesions Following Sinus Surgery

N/A

Strain isolation from the nasopharynx

Bordetella Pertussis, Whooping Cough

N/A

Interview Prep Quick Facts

Portfolio: 298 approved products, 170 clinical trials

Top TAs: Oncology, Metabolic Diseases, Infectious Diseases

H-1B (2023): 1 approval

Publications: 25 in PubMed

Open Roles: 1145 active jobs

Portfolio Health

Pre-Launch69 (23%)

Launch1 (0%)

Growth4 (1%)

Peak22 (7%)

LOE Approaching131 (44%)

Post-LOE71

Therapeutic Area Focus

Oncology

48 marketed764 pipeline

Metabolic Diseases

29 marketed380 pipeline

Infectious Diseases

24 marketed348 pipeline

Neurology

21 marketed144 pipeline

Hiring Trend

Actively Hiring

1145

Open Roles

+448

Added

-290

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (1)

2024-04-29

— Cambridge, MA

source

Source: state DOL filings, aggregated via Big Local News

2 active drug shortages

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

NAStructuralDB : structural database to facilitate computational studies of molecular modeling and recognition of proteins with special focus on antibody-antigen interactions.

mAbs

2026

PMID:41797001

Dupilumab subgroup responder analysis: a post hoc analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis.

NCT00120172Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer

Phase 2

NCT04959448Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

N/A

NCT00539032Immunology and Safety of Menactra® in Children in Saudi Arabia

Phase 3

NCT00103610Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients

Phase 3

NCT00778479Evaluation of the Safety of Sepraspray in Open Abdominal Surgery

N/A

NCT00929318Influence of Thyroid Hormones on the Woundhealing Process

N/A

NCT02765828Identification of Tongue Involvement in Late-Onset Pompe Disease

N/A

NCT03643328Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients

N/A

NCT02633787Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

Phase 4

Respiratory

25 marketed130 pipeline

Rare Diseases

11 marketed143 pipeline

Immunology

27 marketed122 pipeline

Cardiovascular

21 marketed104 pipeline

No recent regulatory warnings or warn layoff filings detected; 2 active drug shortages (rifapentine, rifampin) do not suggest systemic manufacturing crisis—baseline risk profile favorable.

The Journal of dermatological treatment

2026

PMID:41808464

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Sanofi(SNY)

Should You Work at Sanofi?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (48)

Key Products by Revenue

Other Products (24)

Pipeline & Clinical Trials

Open Jobs (1145)

Area Business Manager Pulmonary, Spokane, WA

US Medical Director, Aggressive Systemic Mastocytosis (aSM)

US Medical Director, Indolent Systemic Mastocytosis (ISM)

Head, Health System Strategy, Rare Diseases

Associate Director, US Consumer Analytics

Strategic Account Manager Vaccines, Los Angeles, CA

Strategic Account Manager Vaccines, South Los Angeles, CA

Production Technician-2nd Shift

Production Technician

Production Technician

Head of Vaccine Research and Development Project Management

Area Business Manager Hematology/Oncology, Fort Wayne, IN

TA Head for Patient-Driven Outcomes Research

Senior Distinguished Scientist for Transgenic Model and Technology

Clinical Educator, Tzield, Mid Atlantic (VA, DC, NC, SC, East TN)

Quality Assurance Specialist

Production Technician

Principal Scientist - CMC Statistician

Field Reimbursement Manager, Respiratory and Dermatology, Tampa South, FL

Area Business Director, Los Angeles, CA

Global Safety Officer

Distinguished Scientist, Safety Assessment Project Expert

Principal Scientist

Senior Director, Access Strategy, Rheumatology

Engagement Lead

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)

Research Publications(10)